Guardant Health Overview
- Founded
-
2011
- Status
-
Public
- Employees
-
1,793
- Stock Symbol
-
GH
- Investments
-
5
- Share Price
-
$27.94
- (As of Friday Closing)
Guardant Health General Information
Description
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
Contact Information
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Laboratory Services (Healthcare)
Stock Exchange
NAS
Primary Office
- 505 Penobscot Drive
- Redwood City, CA 94063
- United States
+1 (855) 000-0000
Guardant Health Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $27.94 | $28.26 | $24.20 - $77.72 | $2.87B | 103M | 2.21M | -$6.41 |
Guardant Health Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 3,201,641 | 3,201,641 | 10,100,336 | 11,974,557 |
| Revenue | 449,538 | 449,538 | 373,653 | 286,730 |
| EBITDA | (620,979) | (620,979) | (363,552) | (235,244) |
| Net Income | (654,588) | (654,588) | (405,670) | (253,783) |
| Total Assets | 1,609,985 | 1,609,985 | 2,204,499 | 2,271,781 |
| Total Debt | 1,369,284 | 1,369,284 | 1,373,730 | 854,489 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Guardant Health Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Guardant Health Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Guardant Health Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research
Diagnostic Equipment
Redwood City, CA
1,793
As of 2022
00000
000000 - 000
00000
00000
lore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco la
0000000000 000000000
Madison, WI
0000
As of 0000
00.000
00000000
00.000
000000
tetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magn
0000000000000
San Carlos, CA
0000
As of 0000
00000
000000 - 000
00000
Add Comparison
Guardant Health Competitors (27)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Exact Sciences | Formerly VC-backed | Madison, WI | 0000 | 00.000 | 00000000 | 00.000 |
| 000000 | Formerly VC-backed | San Carlos, CA | 0000 | 00000 | 000000 - 000 | 00000 |
| 00000000 | Formerly VC-backed | Boulder, CO | 000 | 00000 | 000000000 | 00000 |
| 000000000 | Venture Capital-Backed | Siena, Italy | 00 | 0000000000 0 | ||
| 000000000000 00000 | Corporate Backed or Acquired | Elmwood Park, NJ | 0000 | 000000&0 |
Guardant Health Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Guardant Health Patents
Guardant Health Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230083814-A1 | Methods for early detection of cancer | Pending | 19-Oct-2022 | 0000000000 | |
| US-11578374-B2 | Systems and methods to detect rare mutations and copy number variation | Active | 16-Mar-2022 | 0000000000 | 000 |
| US-20220344004-A1 | Detecting the presence of a tumor based on off-target polynucleotide sequencing data | Pending | 09-Mar-2021 | 000000000 | |
| US-20220411876-A1 | Methods and related aspects for analyzing molecular response | Pending | 05-Mar-2021 | 0000000000 | |
| US-20220154286-A1 | Compositions and methods for analyzing dna using partitioning and base conversion | Pending | 23-Oct-2020 | C12Q1/6886 |
Guardant Health Executive Team (29)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| AmirAli Talasaz Ph.D | Chief Executive Officer & Founder | ||
| Helmy Eltoukhy Ph.D | Co-Founder, Co-Chief Executive Officer & Chairman of the Board | ||
| Michael Bell | Chief Financial Officer | ||
| Irfan Shah | Director, BioPharma Business Development | ||
| Chris Freeman | Chief Commercial Officer |
Guardant Health Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Helmy Eltoukhy Ph.D | Guardant Health | Co-Founder, Co-Chief Executive Officer & Chairman of the Board | 000 0000 |
| Ian Clark | Self | Board Member | 000 0000 |
| Meghan Joyce | Guardant Health | Board Member | 000 0000 |
| Samir Kaul | Khosla Ventures | Board Member | 000 0000 |
| Stanley Meresman | Self | Board Member | 000 0000 |
Guardant Health Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Guardant Health Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Guardant Health Investments & Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 0000 | 13-Jun-2022 | 0000000000 | 00000 | Biotechnology | 00000 000 |
| 00000 | 19-Jul-2021 | 00000 0000 | 0000 | Decision/Risk Analysis | 00000 000 |
| 00000000000.0 | 25-Jun-2021 | 00000 0000 | 000.00 | Decision/Risk Analysis | 0000000 0 |
| 0000000000 00 | 24-Apr-2019 | 0000000000 | 00.00 | Biotechnology | 0000000 0 |
| Guardant Health AMEA | 01-May-2018 | Joint Venture | Biotechnology | 00000 000 |
Guardant Health Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000000 000000 00 | Biotechnology | Singapore, Singapore | 0000 |
Guardant Health ESG
Risk Overview
Risk Rating
Updated November, 18, 2022
28.86 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.00
Percentile
Healthcare
Industry
00 of 601
Rank
00.00
Percentile
Medical Services
Subindustry
00 of 108
Rank
00.0
Percentile
